Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06826647 in healthy subjects and subjects with plaque psoriasis
NCT03210961Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ropsacitinib in plaque psoriasis (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period) at Day 8, Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period) at Day 28 and 14 more. Started Jul 2017; status: completed.
02
Drugs
ropsacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03210961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210961.